ETT.png

Light Line™ Vascular

Light Line™ Vascular

Although a 46% decrease in CLABSIs has occurred in hospitals across the U.S. from 2008-2013, an estimated 30,100 central line-associated bloodstream infections (CLABSI) still occur in intensive care units and wards of U.S. acute care facilities each year [1]. CLABSIs are serious infections typically causing a prolongation of hospital stay and increased cost and risk of mortality.

Vascular catheters fail to translate clinical needs of long term infection prevention to improved outcomes using existing technology. Drug coatings have been the subject of multiple studies looking at reducing catheter related blood-bloodstream infections (CRBSI). While reports vary [2], [3], [4], they seem to suggest effectiveness diminishes substantially in long term catheter use [5]. Metallic coatings seem to not have much benefit [6] and are not clinically used much in vascular catheters. Drug and chemical coatings, ointments and lock solutions are commonly used, but also increase the potential for antibiotic resistance due to development of bacterial protective mechanisms like biofilm formation. The National Healthcare Safety Network reported as much as 83% of bloodstream infections caused by certain bacteria were the drug-resistant species [7]. They also reported that 20-40% of all HAIs were from drug-resistant species. It is clear that antibiotic treatments are not a long-term solution to stop HAIs and save lives. 

IMG_0156_2.png

 

References

  1. CDC National and State Healthcare-Associated Infections Progress Report, published March 2014, available at www.cdc.gov/HAI/pdfs/progress-report/hai-progress-report.pdf
  2.  Raad II, Darouiche RO, Hachem R, Abi-Said D, Safar H, Darnule T, Mansouri M, Morck D. Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin. Crit Care Med. 1998;26(2):219-24. PubMed PMID: 9468157.
  3. Rabindranath KS, Bansal T, Adams J, Das R, Shail R, MacLeod AM, Moore C, Besarab A. Systematic review of antimicrobials for the prevention of haemodialysis catheter-related infections. Nephrol Dial Transplant. 2009;24(12):3763-74. doi: 10.1093/ndt/gfp327. PubMed PMID: 19592599.
  4. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis. 2004;44(5):779-91. PubMed PMID: 15492943.
  5. Darouiche RO, Raad II, Heard SO, Thornby JI, Wenker OC, Gabrielli A, Berg J, Khardori N, Hanna H, Hachem R, Harris RL, Mayhall G. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med. 1999;340(1):1-8. doi: 10.1056/NEJM199901073400101. PubMed PMID: 9878638.
  6. Trerotola SO, Johnson MS, Shah H, Kraus MA, McKusky MA, Ambrosius WT, Harris VJ, Snidow JJ. Tunneled hemodialysis catheters: use of a silver-coated catheter for prevention of infection--a randomized study. Radiology. 1998;207(2):491-6. doi: 10.1148/radiology.207.2.9577500. PubMed PMID: 9577500.
  7. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, Facilities NHSNNTaPN. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1-14. doi: 10.1086/668770. PubMed PMID: 23221186.